Day: July 2, 2025

Attempts Underway to Fix Gap in SA’s Plan to Fight Cancer

A cancer patient receiving care at a public health facility in Gauteng. (Photo: Rosetta Msimango/Spotlight)

By Chris Bateman

Experts say cancer patients in the public sector in South Africa are dying for avoidable reasons like dysfunctional referral systems and a lack of medical imaging and treatment. We look at efforts to get the country’s battle with cancer back on track.

Many people with cancer in Gauteng have not been able to access the treatment and care they require in recent years. Though activists and the provincial government are at odds about what should, or should have been, done about it, nobody is denying that there is a problem.

At the same time, there have also been issues at a national level, with South Africa’s key cancer strategy having lapsed. The National Cancer Strategic Framework for South Africa 2017 – 2022 was previously extended to also cover 2023. Medical Brief recently reported that a new strategy is on the verge of being signed by the Director-General of Health.

The committee meant to advise the minister on cancer has also lapsed. Dr Busisiwe Ndlovu, the top government official in charge of non-communicable diseases (NCDs), said that the term of the Ministerial Advisory Committee on Cancer expired in early 2024, and new members were pending the approval of Health Minister Dr Aaron Motsoaledi. She was speaking at the KwaZulu-Natal leg of a cancer research and innovation strategy workshop in May. These consultative meetings are taking place across the country’s provinces. It aims to shape a national research and innovation strategy based on the World Health Organization’s cancer control pillars: prevention, early detection and diagnosis, treatment, and palliative care and survivorship.

The scale of the problem

While researchers anticipate that rates of infectious diseases like HIV and tuberculosis in South Africa will decline in the coming decade or two, rates of NCDs, including diabetes and cancers, are expected to increase. According to the WHO, an estimated one in five people will develop some form of cancer in their lifetimes. Increases in developing countries are expected to be particularly steep.

According to a StatsSA report published in 2023, and based on National Cancer registry (NCR) numbers and StatsSA’s mortality data, cancer-related deaths in the country increased by 29% from 2008 to 2018. They reported that 85 000 people were diagnosed with cancer in 2019 and that 44 000 died of cancers in 2018. Experts previously told Spotlight that the estimate of cancer cases may be an undercount of as much as 40%.

The most common cancers in men were prostate, colorectal, and lung – around one in four cancer diagnoses in men were for prostate cancer. Bronchus and lung cancer accounted for just under 19% of cancer-related deaths in men, while prostate cancer accounted for around 17%.

Among women, the most diagnosed cancers were breast cancer at around 23% of diagnoses and cervical cancer at around 16% of diagnoses. Cervical cancer accounted for just under 18% of all cancer deaths in women and breast cancer for 17%.

The NCR recorded 87 853 new laboratory-confirmed cancer cases in 2023, although this figure likely underestimated the true burden as it excluded clinically or radiologically diagnosed cancers, Dr Judith Mwansa-Kambafwile, senior epidemiologist with the NCR told attendees at the Durban workshop.

In a paper published in the South African Journal of Oncology in 2022, researchers calculate that cancer incidence (new cases per year) in South Africa could double from around 62 000 in 2019 to 121 000 in 2030. This is due to two factors: firstly, South Africa’s population is aging and cancers generally become more common as people age. And secondly, the risk of cancers is generally increasing for people of all ages. The researchers focused on only the five most common types of cancer, but an NCR report shows a very wide variety of cancers are being diagnosed in the country.

Since not all cancers are diagnosed, the real numbers are likely substantially higher than reported. There is also no single repository of all cancer diagnoses in the country – for the above quoted article researchers used both data from Discovery Health Medical Scheme and from the NCR.

The data gap

Cancer statistics in South Africa has been largely based on pathology results, which is to say blood or biopsies that were tested in the lab. Other types of diagnoses, such as those based on symptoms and scans have not always been counted systematically. One recent initiative aimed at addressing this data gap is a patient-led registry that feeds information into the NCR.

Mwansa-Kambafwile, explained that the NGO, Living with Cancer, was driving the patient-led registry, aimed at cross referencing and supplementing patient records with her NCR’s own patient database. Leaflets in oncologists’ reception rooms encouraged patients to upload their pathology/histology test results onto the Living with Cancer website via a standard online National Department of Health form. A national shopping mall campaign in May was aimed at boosting awareness.

“Living with Cancer had a Memorandum of Understanding with us and in addition, links cancer survivors with the same type of cancer to one another in support groups online where they can share experiences and knowledge,” she added.

Dr Mazvita Muchengeti, who heads up work on the NCR at the National Health Laboratory Services which is part of the National Institute for Communicable Diseases (NICD), previously told Spotlight that cancer was made a reportable disease under the National Health Act in 2011. While compulsory reporting has improved data on cancer cases, she added: “There is an increase in the number of reported cancers; this does not necessarily translate to an increase in cancer, we are just counting cancer cases better because reporting is now compulsory.”

Another new strategy

In light of the country’s cancer burden, a group of organisations is leading the development of a new National Cancer Research and Innovation Strategy. This collective includes the Nuclear Medicine Research Infrastructure at the University of Pretoria, the South African Medical Research Council, and the Department of Science, Technology and Innovation, in partnership with the National Department of Health.

They are hosting provincial workshops to help understand the current state of cancer research in South Africa, identify key challenges, set national priorities, and develop a strong, future-focused strategy. These workshops are part of a broader plan to make sure the strategy is inclusive, based on evidence, and meets the country’s needs.

This research and innovation strategy differs from the health department’s National Cancer Strategic Framework, which guides provinces as to what the cancer priorities are.

‘Integrated cancer care approach’

At the Durban workshop, Ndlovu, emphasised the need for an integrated cancer care approach across all levels of the healthcare system. She noted the importance of streamlined referral pathways and urgent attention to waiting times, care packages, registry improvements, and financing. The expired national cancer strategy required urgent evaluation and revision, Ndlovu added.

A clear pattern emerging from these workshops is one whereby cancers are often diagnosed too late, and patients frequently struggle to access timely, appropriate care.

Also at the Durban workshop, Professor Jeannette Parkes, Head of Radiation Oncology at Groote Schuur Hospital and the University of Cape Town, outlined the many systemic barriers to early detection. These included socio-cultural factors, urban-rural divides, and broken referral systems.

“We have a massive issue with accessing imaging services, biopsy support, pathology services, and their costs,” she said.

Parkes, who is also President of the College of Radiation Oncology of South Africa and clinical director of the Access to Care Cape Town programme, said early cancer detection was better in the private sector because patients could access and afford the necessary systems and diagnostic technology. The remaining 85% of the population depended on the public sector, in particular overburdened primary healthcare clinics but also on all levels of care.

“There’s a bias towards urban versus rural areas and too often a failure to refer. The referral pathway is problematic and differs from province to province and in various settings. We have a massive issue with regards to accessing imaging services, while biopsy support and pathology services and their costs are also a big issue,” she told the workshop.

Late diagnosis

At the Johannesburg meeting, late diagnosis was singled out as a particular problem when it comes to cervical cancer. Dr Mary Kawonga, public health specialist with the Gauteng Department of Health and Wits School of Public Health, said that 16% of women screened at Charlotte Maxeke Academic Hospital’s drainage district had pre-cancerous lesions, underlining the lack of preventative care. “Patients often only begin treatment on their sixth visit,” she said, citing the failure of diagnostic tools, referral inefficiencies, and poor implementation of available technologies.

Dr Mariza Vorster, Head of Nuclear Medicine at the University of KwaZulu-Natal and Inkosi Albert Luthuli Academic Hospital, said that insufficient specialists and excessive patient loads result in unacceptable turnaround times for diagnosis.

Clinicians often get blamed for delays, but as Dr Sheynaz Bassa, Head of Radiation Oncology at Steve Biko Academic Hospital, pointed out, many patients wait weeks or months to afford transport to care facilities. “By the time they get to us, they’re already in crisis mode,” she said. “Peripheral clinics and hospitals must improve referral systems before we can make real progress.”

Salomé Meyer, Director of Cancer Alliance, alleged that survivorship care is almost entirely absent in both the public and private sectors. “Supportive and palliative care often ends when treatment stops. Survivors are left without co-ordinated care,” she said.

Apart from improving screening and referral systems, other recommendations emerging from the workshops included better coordination between clinicians and the NCR, leveraging mobile technology like the health department’s Mom Connect app to reduce clinic visits and fast-track referrals. Greater community involvement in setting research priorities, using mobile clinics to conduct cancer screening in rural areas, and increasing awareness for breast self-examination. More research into the genetic factors relating to cancers in South Africa was also argued for.

Call for new cancer institute

Meyer has been leading a call for South Africa to establish a National Cancer Institute (NCI).

“An NCI would develop clear guidelines on treatment protocols, workforce allocation, and facility requirements,” she said. With South Africa transitioning toward a National Health Insurance system, Meyer said an NCI would help plan resource allocation based on cancer projections, enabling smarter investments in infrastructure, technology, and staffing.

The lapsed National Cancer Strategic Framework lacked province-specific detail, leaving provinces to adapt guidelines as they saw fit, often leading to fragmented service delivery, she added. Meyer said decentralisation was essential. “We can no longer restrict cancer treatment to tertiary hospitals. Many district and regional facilities could provide diagnostics and some treatments if properly resourced,” she said.

A reset of South Africa’s disease monitoring and research infrastructure has been on the cards for some time. The NICD was set to be replaced by the new National Public Health Institute of South Africa (NAPHISA) after the NAPHISA Act became law in 2020. Five years later, NAPHISA has not yet been established. On the face of it, NAPHISA would be a natural home for an entity like the proposed NCI were it to be created.

–  Additional reporting by Marcus Low

Republished from Spotlight under a Creative Commons licence.

Read the original article.

Opinion Piece: Why Employee Benefits Need to Go Beyond Medical Aid

By James White, Director of Sales and Marketing at Turnberry Management Risk Solutions

Photo by Alex Green on Unsplash

Rising medical costs can be a major burden that negatively affects employees’ health, wellness and productivity. Even with medical aid in place, unexpected shortfalls for hospital stays, surgeries and specialist treatments can run into tens of thousands of Rands – creating financial stress that spills over into the workplace.

Group gap cover offers an affordable, accessible and highly effective way to bridge the growing divide between what medical schemes pay and what private healthcare actually costs. This makes a tangible difference for both employers and their employees.

A practical solution for reducing stress and improving productivity

Medical expense shortfalls can add up to significant amounts of money and can be enough to seriously impact an individual’s financial wellbeing. Employees who cannot afford the co-payments or gaps in cover may delay treatment, manage ongoing pain with temporary measures, or fall back on high-interest loans, all of which can negatively affect their focus and performance at work.

Group gap cover can help to prevent this type of scenario. Cover includes medical expense shortfalls, co-payments, and sub-limits, and some providers also offer value-added benefits like casualty cover, trauma counselling or additional cancer cover, depending on the plan.

This allows employees to access the care they need without having to worry about paying large sums of money out of their own pocket. It helps them get treatment sooner, making it more likely they will recover faster and return to work sooner, as well as offering improved peace of mind. All of this benefits the business as much as the individual.

Empowering brokers to support a broader wellness strategy

Brokers are ideally placed to support employers in designing employee benefits that do more than tick boxes by positioning group gap cover as an essential component of an organisation’s wellness strategy.

It is, however, essential to tailor group gap cover plans to align with the medical aid options that are already in place. The key is to create solutions that fit the needs of the organisation and its employees and add tangible value, taking into account elements like demographics, income bracket, life stage and so on. For brokers, this is an opportunity to drive innovation in employee benefits and demonstrate deeper advisory value.

Affordability that matters in a tough economy

As medical inflation continues to outpace the Consumer Price Index (CPI), comprehensive medical aid has become less attainable for many companies and their employees. Some organisations have been forced to downgrade their medical scheme contributions, leaving employees more exposed to shortfalls. Group gap cover offers a cost-effective way to mitigate that risk.

With preferential premiums, favourable underwriting terms, and often no waiting periods, group gap cover is cost-effective and affordable, especially when compared to the costs of upgrading a comprehensive medical aid plan that will typically also experience certain shortfalls. It is also tax efficient as a payroll deduction and can be implemented with minimal administrative burden.

Attracting and retaining talent in a competitive market

Today’s job seekers are looking for more than a payslip. They want to feel valued and supported. Offering group gap cover as part of a holistic benefits package can set a company apart, especially in sectors where high turnover is common.

Candidates take note when employers show they care about more than just performance metrics. A company that helps its people avoid financial distress during a medical emergency is a company that builds loyalty, trust and long-term engagement. Gap cover is an investment in human capital that pays dividends far beyond the balance sheet.

Genuine benefits build genuine loyalty

Medical costs are rising, and economic pressures are continually increasing. In such an environment, employers need benefits that do more than look good on paper – they need to add real value to the lives of their employees. Group gap cover is one of the most practical, cost-effective ways to support employees’ health and financial wellbeing while also protecting business performance.

By helping people access the treatment they need without incurring crippling debt, it reduces stress, shortens recovery time and fosters loyalty. For businesses looking to attract and retain talent, boost productivity and show genuine care for their people, group gap cover is a benefit that makes a real and lasting difference.

About Turnberry Management Risk Solutions

Founded in 2001, Turnberry is a registered financial services provider (FSP no. 36571) that specialises in Accident and Health Insurance, Travel Insurance, and Funeral Cover.

With extensive experience across healthcare and insurance industries in South Africa, Turnberry offers unsurpassed service to Brokers and clients. Turnberry’s gap cover products are available to clients on all medical aid schemes, as they are independently provided and are therefore transferable in the event of a change in the client’s medical aid scheme.

Turnberry is well represented nationally, with its Head Office based in Bedfordview, Johannesburg with Business Development Managers in Cape Town and Durban. The Turnberry Team’s focus on outstanding client service comes from having extensive knowledge and experience in the financial services sector and is underwritten by Lombard Insurance Company Limited. Lombard Insurance Company Limited is an Authorised Financial Services Provider (FSP 1596) and Insurer conducting non-life insurance business.

Opinion Piece: Rewriting the Rules of Health Insurance

By Shaun Raizenberg, Employee Benefits Consultant at Essential Employee Benefits

Photo by Scott Graham on Unsplash

The health insurance sector is undergoing significant changes that insurers, healthcare professionals and brokers need to be aware of. For one, healthcare costs have risen above the national inflation rate, forcing individuals and corporate entities to reassess their healthcare management strategies.

The industry is moving towards a more personalised and customer -focused approach, companies are revolutionising traditional insurance processes with digital platforms that offer simplicity, transparency and efficiency. The role of technology and data are driving forces behind these trends. With technological advancements reshaping health insurance, other trends like shifting demographics, an ageing population, and rising chronic diseases add complexity. Navigating this landscape requires specialised knowledge. This is where health insurance brokers become essential partners for companies in need of top-quality healthcare solutions for their workforce.

Shifting patterns in the health insurance market

The health insurance industry is currently experiencing significant changes driven by various factors. Healthcare expenditures and utilisation have increased dramatically in recent years given the prevailing South African economic climate and rising healthcare costs. Organisations are scrutinising their healthcare programmes, including those that provide cover for employees. Many employers are now adopting a hybrid approach that includes both medical scheme membership and health insurance to offer maximum flexibility and choice to their workers.

The healthcare sector is also witnessing an increasing adoption of digital solutions; mobile applications with online portals for accessing benefits and services. Users can take advantage of virtual healthcare solutions, such as telemedicine consultations and online appointment scheduling, which not only reduce costs but also save time. Consequently, brokers are focusing on partnering with insurers who offer technologically advanced and user-friendly digital services.

Challenges faced in the market

The health insurance market is facing several challenges. A significant hurdle is the issue of member education. There is a widespread misconception that health insurance operates in the same manner as medical scheme cover, leading to confusion and disappointment among members. Brokers play a crucial role by clarifying the distinctions between each type of cover, and they conduct annual assessment sessions to keep clients informed about new developments or available improvements. Frequent engagements that elucidate various aspects of their benefits empower clients to make more informed decisions.

The healthcare distribution system introduces another layer of complexity as it plays a critical role in ensuring the safe and efficient delivery of healthcare products to patients and healthcare providers. South Africa’s market comprises both public and private sectors, making it difficult to identify and reach the ideal target audience. The insurance sector is heavily competitive, characterised by numerous insurers, each offering a wide range of products. These challenges are compounded by regulatory bodies, stringent rules and requirements that organisations must navigate while attempting to earn customer trust.

Financial pressures significantly impact clients’ decisions regarding attaining affordable healthcare. Financial limitations forces clients to make difficult choices often prioritising essential expenses and, leading many to opt for cheaper health insurance plans even if they have higher out-of-pocket costs or limited cover. Clients who are struggling financially need guidance and sound advice in exploring their options for affordable solutions. By reviewing their existing healthcare costs and assessing their current cover, brokers and insurers can help recommend a more effective healthcare solution that suits their needs. Clients can also consult with a financial advisor to help create a budget that incorporate healthcare costs that includes an emergency fund to cover unexpected additional medical expenses.

The value of consulting health insurance brokers

Given these complexities, one may question why companies should consult health insurance brokers. The answer lies in their expertise and advocacy. Brokers possess in-depth market knowledge and understand insurance products, enabling them to devise tailored solutions that precisely meet the requirements of both companies and employees. They represent their clients in negotiations, ensuring regulatory compliance and striving to secure the best rates and terms while providing ongoing support.

Strategic partnerships: selecting the right insurer

Choosing the right insurance partner is crucial, and brokers focus on several key attributes during this selection process. The insurance company must exhibit sound financial health, offer a comprehensive suite of products and services, and maintain effective claims procedures alongside superior customer care. Additionally, brokers seek partners that demonstrate a commitment to technology and innovation as a means of enhancing the customer experience.

Also, in today’s landscape, an insurance company’s reputation is of paramount importance, as policyholders can easily access customer feedback on social media.

Enhancing the South African healthcare system

The South African healthcare system requires careful navigation. With the assistance of informed and professional brokers, companies can tackle prevailing issues, optimise their healthcare expenditure, and deliver valuable benefits to their employees, ultimately resulting in a healthier and more productive workforce. Brokers serve not only as a source for insurance products but also as providers of expertise and trust, acting on behalf of the client in a complex and dynamic environment.

Microplastics Detected in Human Reproductive Fluids

Photo by FLY:D on Unsplash

New research presented today at the 41st Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) reveals the presence of microplastics in human reproductive fluids, raising important questions about their potential risks to fertility and reproductive health.[1]

The study abstract appears in Human Reproduction, one of the world’s leading reproductive medicine journals.

Researchers examined follicular fluid from 29 women and seminal fluid from 22 men, both of which play critical roles in natural conception and assisted reproduction.

A range of commonly used microplastic polymers, including polytetrafluoroethylene (PTFE), polystyrene (PS), polyethylene terephthalate (PET), polyamide (PA), polypropylene (PP) and polyurethane (PU), were identified in both groups.

Microplastics were present in 69% of the follicular fluid samples analysed. Notably, the most frequently detected polymer was PTFE, found in 31% of the samples. This was followed by PP (28%), PET (17%), PA (14%), polyethylene (PE) (10%), PU (10%) and PS (7%), in descending order of prevalence.

In male seminal fluid samples, microplastics were found in 55% of those analysed. PTFE again emerged as the most prevalent polymer, identified in 41% of the samples. Other polymers detected included PS (14%), PET (9%), PA (5%), and PU (5%), though in lower concentrations.

To prevent contamination, all samples were collected and stored in glass containers and underwent chemical treatment before analysis using laser direct infrared microscopy.

Lead researcher Dr. Emilio Gomez-Sanchez commented, “Previous studies had already shown that microplastics can be found in various human organs. As a result, we weren´t entirely surprised to find microplastics in fluids of the human reproductive system, but we were struck by how common they were – found in 69% of the women and 55% of the men we studied.”

Microplastics are defined as plastic particles under 5mm in size, and there is evidence that they pose a threat to environmental and public health.[2] While this research did not directly assess how microplastics affect fertility, their detection highlights the need to explore possible implications for human reproductive health.

“What we know from animal studies is that in the tissues where microplastics accumulate, they can induce inflammation, free radical formation, DNA damage, cellular senescence, and endocrine disruptions”, continued Dr Gomez-Sanchez. “It’s possible they could impair egg or sperm quality in humans, but we don’t yet have enough evidence to confirm that.”

The research team plans to expand their analysis to a larger cohort, alongside detailed lifestyle and environmental exposure questionnaires. Further phases of the project will also explore the potential relationship between the presence of microplastics and oocyte and sperm quality.

Dr Gomez-Sanchez stressed that fertility is influenced by many factors, including age, health, and genetics, and that the findings should not cause alarm among those trying to conceive. “There’s no need for alarm at this point. Microplastics are just one of many elements that may play a role in fertility. However, it is sensible to consider ways of reducing our exposure to them. Simple steps, such as using glass containers to store and heat food, or limiting the amount of water we consume from plastic bottles, can help minimise our intake.”

Source: Focus on Reproduction

References:

[1] Gomez-Sanchez, E., et al. (2025) Unveiling the Hidden Danger: Detection and characterisation of microplastics in human follicular and seminal fluids. Human Reproduction. [insert link when available]

[2] Wang, L., Yin, Y., & He, X. (2024). The hidden threat: Unraveling the impact of microplastics on reproductive health. Science of the Total Environment, 912, 173177.

Multiple Sclerosis Drug Ocrelizumab Works by Reshaping the Immune System

Myelin sheath damage. Credit: Scientific Animations CC4.0

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered patients immense hope. The long-awaited drug is a monoclonal antibody that depletes B cells – the immune cells that drive MS progression. Exactly how ocrelizumab does this, however, remains unclear.

In a new study published in The Journal of Clinical Investigation, Yale scientists begin to answer this question. By using single-cell RNA sequencing, a technique that provides a window into the gene expression in individual cells, the researchers laid out a detailed view of how ocrelizumab achieves its therapeutic effects.

“The surprise was that the drug doesn’t work at all the way we thought it was working,” says David A. Hafler, MD, Professor of Neurology at Yale School of Medicine, who led the study. “We knew what the end result was and that the drug was enormously effective in patients. But what’s driving the drug’s action is a type of white blood cell in the central nervous system. No one would ever hypothesise that.”

The roles of T cells and B cells in multiple sclerosis

B and T cells have closely intertwined roles in the immune system. B cells are critical cells that recognise foreign objects, bind them, and present them to T cells, which then signal other immune cells to take action. But this relationship goes awry in disease.

Scanning electron micrograph of a B cell. Credit: NIH

In MS, abnormally active B cells trigger T cells to attack the myelin sheath, the protective layer of nerve fibres, leading to neurological symptoms, such as loss of vision, muscle weakness, and cognitive impairment. More than two decades ago, Hafler and his team discovered this was due to defects in regulatory T cells, which normally put the brake on immune responses, but when defective, unleash immune cells that mistakenly target the body’s own tissues.

In the early stages of MS, both B and T cells are deemed to be the drivers of the disease. Once the disease progresses to a neurodegenerative stage, other inflammatory processes become more prominent.

“Once you enter the neurodegenerative phase of the disease, it is much more difficult to stop the process,” Hafler says. “What we’ve learned is that the earlier you treat the disease, the better the outcome.”

Ocrelizumab binds to the surface of B cells, leading to their destruction. And especially for people in the early stages of MS, it can be quite effective. “The drug works incredibly well,” Hafler says. But Hafler and his team found that ocrelizumab was doing far more than just controlling B cells.

In the new study, the researchers analysed the blood and cerebrospinal fluid of 18 patients, all of whom had an early-onset form of multiple sclerosis in which patients cycle between periods of disease remission and relapse. The scientists measured the cell type-specific changes in protein expression before and after the patients received six months of ocrelizumab, in an effort to identify immune molecules that might change in response to the drug.

They discovered that the reduction in B cells driven by ocrelizumab led to an increase in the pro-inflammatory molecule TNF-α. This was unexpected because TNF-α has been shown to trigger the immune system and exacerbate inflammation in certain diseases. In fact, medications that block the activity of TNF-α are typically used for treating various autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.

As they looked further, the researchers found that by inducing TNF-α, ocrelizumab led to an increase in a specific type of regulatory T cell. This, in turn, curbed the circulation of T cells that attack the myelin.

“This unpredicted increase in TNF-α shows that ocrelizumab works in a paradoxical way,” says Hafler.

Understanding the cause of multiple sclerosis

One of the current working models of MS suggests that the disease originates from the Epstein-Barr virus. “How the Epstein-Barr virus triggers the disease is a point that we don’t yet understand,” Hafler says. However, there is a strong body of evidence to show that the virus infects B cells. Therefore, understanding how a B cell-depleting drug affects T cell activity may lead to further explanations.

The current finding also explains why a fifth of the genes linked to MS risk involve the TNF pathway and why many of those genetic changes are protective in other diseases, such as inflammatory bowel diseases.

“This shows that biology has a richness to it,” Hafler says. “When these molecules are made, where they’re made, and what cell they’re working on have very different effects.”

Hafler suspects that ocrelizumab might be acting through other mechanisms as well, an inkling that motivates his lab to continue their investigation. “For something to work that well, there must be other things going on,” he says.

The team is now beginning to study the pathogenesis of MS in a large cohort of women who have at least one parent with the disease. By following the genetic evolution of the disease, the scientists are hoping to better understand how B cells change the immune landscape in real time.

“This study is only one piece of the puzzle,” Hafler says. “We’ll continue to look for other pieces.”

Source: Yale School of Medicine

An Early Night is Linked to More Physical Activity than Burning the Midnight Oil

Photo by Ketut Subiyanto on Unsplash

Going to bed earlier than usual may help to optimise physical activity the following day, Monash University-led research has found.

Published in Proceedings of the National Academy of Sciences (PNAS), the study examined whether sleep duration and sleep timing were associated with the duration of moderate-to-vigorous and overall physical activity the following day.

In the primary study, almost 20 000 participants wore a validated biometric device (WHOOP) for one year, resulting in almost six million nights of data. Objective sleep and physical activity metrics were derived from the wrist-worn device.

The study examined how both typical sleep habits and nightly fluctuations in sleep were linked to next-day physical activity levels.

On average, people who went to bed earlier were more physically active. For example, those with a typical bedtime around 9pm logged about 30 more minutes of moderate-to-vigorous physical activity each day compared to those who regularly stayed up until 1am.

Even compared to those who typically went to bed at 11pm (the average bedtime for the entire sample), the 9pm sleepers recorded nearly 15 additional minutes of daily moderate-to-vigorous physical activity.

Lead author Dr Josh Leota, from Monash University’s School of Psychological Sciences, said the findings suggested individuals with later bedtimes may be at a disadvantage under conventional work schedules.

“Standard 9-to-5 routines can clash with the natural sleep preferences of evening types, leading to social jetlag, poorer sleep quality, and increased daytime sleepiness – which can all reduce motivation and opportunity for physical activity the next day,” Dr Leota said.

Importantly, the study also looked at whether individuals can actively alter this relationship. The researchers found that when people went to sleep earlier than usual but still got their typical amount of sleep, they recorded the highest levels of physical activity the next day.

“These insights carry meaningful implications for public health,” Dr Leota said. “Rather than just promoting sleep and physical activity independently, health campaigns could encourage earlier bedtimes to naturally foster more active lifestyles. A holistic approach that recognises how these two essential behaviours interact may lead to better outcomes for individual and community health.”

An additional validation study involving almost 6000 participants from the All of Us Research Program, using Fitbit data, reinforced these findings, showing the relationships were broadly consistent across diverse populations.

Senior author Dr Elise Facer-Childs, from the Monash University School of Psychological Sciences, said that these findings highlight a powerful relationship between sleep timing and physical activity.

“Sleep and physical activity are both critical to health, but until now we didn’t fully grasp how intricately connected they are in everyday life,” Dr Facer-Childs said.

“Our findings are consistent across different populations, and show that if you can get to sleep earlier than usual whilst keeping your sleep duration the same, you may be more likely to increase your physical activity the following day”, says Dr Facer-Childs.

Read the research paper here: DOI 10.1073/pnas.2420846122

Source: Monash University